On This Day in Health: March 1, 2024
On March 1, 2024, the United States Food and Drug Administration approved amivantamab with carboplatin and pemetrexed as an initial treatment for a defined group of people with advanced non-small cell lung cancer. Their tumors carried an insertion mutation in exon 20 of the epidermal growth factor receptor gene, usually shortened to EGFR. Eligibility depended on an approved test identifying that genetic change. The decision brought a targeted antibody into an earlier stage of treatment alongside established chemotherapy. Its importance was specific: it expanded the options for a molecular subgroup whose disease had presented particular treatment difficulties, rather than establishing one new regimen for every lung cancer patient.
Cancer classification increasingly considers changes within tumor cells as well as where a cancer begins. EGFR helps regulate cellular growth, and certain alterations can contribute to uncontrolled division. Exon 20 insertions form a distinct group within EGFR-mutated lung cancer; results for other EGFR mutations cannot simply be assumed to apply to them. Amivantamab is an antibody directed at EGFR and another growth-related receptor, MET. The chemotherapy drugs in the approved combination attack cancer through different mechanisms. Bringing these approaches together illustrates how precision medicine can involve adding a targeted treatment to existing care, rather than replacing all conventional treatment with a single specialized medicine.
The PAPILLON study supplied the central evidence for the first-line combination. It compared treatment strategies in 308 participants, using the time before cancer progression or death as its main outcome. Median progression-free survival was 11.4 months with the antibody combination and 6.7 months with chemotherapy alone. These are summaries of trial groups, not predictions of how long an individual person will benefit. Overall survival data were still developing at the analysis described in the approval announcement. The distinction matters because delaying progression and demonstrating a longer lifespan are related but separate findings. A regulatory milestone should be understood through the outcome actually measured, alongside the questions that remained open.
The treatment also required attention to adverse effects, including reactions during infusion and problems affecting skin and nails. On the same date, the regulator converted an earlier accelerated authorization for amivantamab after platinum chemotherapy into traditional approval. These two decisions concerned different points in the treatment pathway and should not be blended into one indication. March 1 therefore marks both an expansion of first-line choices and a further step in the evidence history of an existing drug. The broader lesson is how testing, clinical trials, and treatment decisions interact: identifying a mutation can open a particular option, but access to that option still depends on appropriate clinical evaluation and the practical ability to deliver care.
An exon 20 insertion identifies a particular subgroup of EGFR-mutated lung cancer. The approval required an authorized test to establish that tumor feature.
The regimen combined a targeted antibody with two chemotherapy medicines. Precision treatment can build on conventional care rather than replace every part of it.
PAPILLON compared the combination with chemotherapy alone in 308 participants. Its principal outcome concerned progression-free survival.
The reported medians summarize groups. They should not be read as an individual forecast or confused with a completed overall survival analysis.
The same date also brought traditional approval for an existing later-line indication. That separate decision followed an earlier accelerated authorization.
A genetic test can identify an option, while infusion delivery and monitoring determine how it can be used. The milestone sits within that larger care pathway.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.